Bruker (NASDAQ:BRKR) Issues FY 2027 Earnings Guidance

Bruker (NASDAQ:BRKR) issued an update on its FY 2027 earnings guidance on Friday morning. The company provided earnings per share guidance of 4.000-4.300 for the period. The company issued revenue guidance of $4.2 billion-$4.4 billion.

Bruker Stock Performance

Shares of NASDAQ BRKR opened at $75.07 on Friday. The company has a debt-to-equity ratio of 0.95, a current ratio of 1.81 and a quick ratio of 0.91. Bruker has a one year low of $53.79 and a one year high of $94.86. The business’s 50-day moving average price is $84.74 and its two-hundred day moving average price is $76.18. The company has a market capitalization of $10.91 billion, a P/E ratio of 27.30, a price-to-earnings-growth ratio of 1.81 and a beta of 1.22.

Bruker (NASDAQ:BRKR) last announced its quarterly earnings results on Thursday, May 2nd. The medical research company reported $0.53 EPS for the quarter, beating the consensus estimate of $0.46 by $0.07. The business had revenue of $721.70 million during the quarter, compared to analysts’ expectations of $729.88 million. Bruker had a return on equity of 27.31% and a net margin of 13.38%. The firm’s quarterly revenue was up 5.3% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.64 EPS. Analysts anticipate that Bruker will post 2.82 earnings per share for the current fiscal year.

Bruker Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, June 17th. Stockholders of record on Monday, June 3rd will be issued a dividend of $0.05 per share. The ex-dividend date is Friday, May 31st. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.27%. Bruker’s dividend payout ratio is currently 7.27%.

Analyst Upgrades and Downgrades

Several equities analysts have commented on BRKR shares. JPMorgan Chase & Co. raised shares of Bruker from a neutral rating to an overweight rating and increased their target price for the stock from $60.00 to $90.00 in a research report on Wednesday, February 14th. UBS Group increased their price objective on Bruker from $94.00 to $102.00 and gave the company a buy rating in a report on Friday, March 1st. Citigroup boosted their target price on Bruker from $80.00 to $95.00 and gave the stock a buy rating in a report on Wednesday, February 14th. The Goldman Sachs Group increased their price target on Bruker from $66.00 to $74.00 and gave the company a sell rating in a report on Wednesday, April 10th. Finally, Stifel Nicolaus boosted their price objective on shares of Bruker from $63.00 to $81.00 and gave the stock a hold rating in a research note on Wednesday, February 14th. One analyst has rated the stock with a sell rating, two have given a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of Moderate Buy and an average price target of $84.86.

Insiders Place Their Bets

In other Bruker news, Director Hermann Fritz Requardt sold 15,000 shares of the company’s stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $90.06, for a total value of $1,350,900.00. Following the completion of the transaction, the director now owns 23,147 shares of the company’s stock, valued at approximately $2,084,618.82. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Company insiders own 28.30% of the company’s stock.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.